ongyx的个人主页 - 老虎社区

ongyx

ongyx

暂无个人介绍

IP属地：未知

2关注

0粉丝

0主题

0勋章

2021-02-23

👍👍👍

BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis<blockquote>简介-欧盟委员会授予Ocugen基因治疗候选产品Ocu400孤儿药品称号，用于治疗色素性视网膜炎和Leber先天性黑蒙</blockquote>

2021-02-05

$GameStop(GME)$lets go guys!!! To the moon!

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3571394615915902","uuid":"3571394615915902","gmtCreate":1608300592873,"gmtModify":1612538742160,"name":"ongyx","pinyin":"ongyx","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1c25a2544a6027a5f0d972b0748443b0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":363049725,"gmtCreate":1614086420667,"gmtModify":1634551237356,"author":{"id":"3571394615915902","authorId":"3571394615915902","name":"ongyx","avatar":"https://static.tigerbbs.com/1c25a2544a6027a5f0d972b0748443b0","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571394615915902","authorIdStr":"3571394615915902"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363049725","repostId":"2113335786","repostType":2,"repost":{"id":"2113335786","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614083671,"share":"https://www.laohu8.com/m/news/2113335786?lang=zh_CN&edition=full","pubTime":"2021-02-23 20:34","market":"us","language":"en","title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis<blockquote>简介-欧盟委员会授予Ocugen基因治疗候选产品Ocu400孤儿药品称号，用于治疗色素性视网膜炎和Leber先天性黑蒙</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","media":"Reuters","summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","content":"<p><html><body>Feb 23 (Reuters) - Ocugen Inc   :</p><p><blockquote><html><body>2月23日（路透社）-Ocugen Inc：</body></html></blockquote></p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p><blockquote>*欧盟委员会授予OCUGEN基因治疗候选产品OCU400孤儿药品称号，用于治疗视网膜色素变性和LEBER先天性黑蒙</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon的源文本：更多公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>（（Reuters.Briefs@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis<blockquote>简介-欧盟委员会授予Ocugen基因治疗候选产品Ocu400孤儿药品称号，用于治疗色素性视网膜炎和Leber先天性黑蒙</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis<blockquote>简介-欧盟委员会授予Ocugen基因治疗候选产品Ocu400孤儿药品称号，用于治疗色素性视网膜炎和Leber先天性黑蒙</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-02-23 20:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>Feb 23 (Reuters) - Ocugen Inc   :</p><p><blockquote><html><body>2月23日（路透社）-Ocugen Inc：</body></html></blockquote></p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p><blockquote>*欧盟委员会授予OCUGEN基因治疗候选产品OCU400孤儿药品称号，用于治疗视网膜色素变性和LEBER先天性黑蒙</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon的源文本：更多公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>（（Reuters.Briefs@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2113335786","content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380649100,"gmtCreate":1612538030300,"gmtModify":1703763402319,"author":{"id":"3571394615915902","authorId":"3571394615915902","name":"ongyx","avatar":"https://static.tigerbbs.com/1c25a2544a6027a5f0d972b0748443b0","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571394615915902","authorIdStr":"3571394615915902"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>lets go guys!!! To the moon!&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>lets go guys!!! To the moon!&nbsp;","text":"$GameStop(GME)$lets go guys!!! To the moon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380649100","isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":363049725,"gmtCreate":1614086420667,"gmtModify":1634551237356,"author":{"id":"3571394615915902","authorId":"3571394615915902","name":"ongyx","avatar":"https://static.tigerbbs.com/1c25a2544a6027a5f0d972b0748443b0","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571394615915902","idStr":"3571394615915902"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363049725","repostId":"2113335786","repostType":2,"repost":{"id":"2113335786","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614083671,"share":"https://www.laohu8.com/m/news/2113335786?lang=zh_CN&edition=full","pubTime":"2021-02-23 20:34","market":"us","language":"en","title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis<blockquote>简介-欧盟委员会授予Ocugen基因治疗候选产品Ocu400孤儿药品称号，用于治疗色素性视网膜炎和Leber先天性黑蒙</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","media":"Reuters","summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","content":"<p><html><body>Feb 23 (Reuters) - Ocugen Inc   :</p><p><blockquote><html><body>2月23日（路透社）-Ocugen Inc：</body></html></blockquote></p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p><blockquote>*欧盟委员会授予OCUGEN基因治疗候选产品OCU400孤儿药品称号，用于治疗视网膜色素变性和LEBER先天性黑蒙</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon的源文本：更多公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>（（Reuters.Briefs@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis<blockquote>简介-欧盟委员会授予Ocugen基因治疗候选产品Ocu400孤儿药品称号，用于治疗色素性视网膜炎和Leber先天性黑蒙</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis<blockquote>简介-欧盟委员会授予Ocugen基因治疗候选产品Ocu400孤儿药品称号，用于治疗色素性视网膜炎和Leber先天性黑蒙</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-02-23 20:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>Feb 23 (Reuters) - Ocugen Inc   :</p><p><blockquote><html><body>2月23日（路透社）-Ocugen Inc：</body></html></blockquote></p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p><blockquote>*欧盟委员会授予OCUGEN基因治疗候选产品OCU400孤儿药品称号，用于治疗视网膜色素变性和LEBER先天性黑蒙</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon的源文本：更多公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>（（Reuters.Briefs@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2113335786","content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":380649100,"gmtCreate":1612538030300,"gmtModify":1703763402319,"author":{"id":"3571394615915902","authorId":"3571394615915902","name":"ongyx","avatar":"https://static.tigerbbs.com/1c25a2544a6027a5f0d972b0748443b0","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571394615915902","idStr":"3571394615915902"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>lets go guys!!! To the moon!&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>lets go guys!!! To the moon!&nbsp;","text":"$GameStop(GME)$lets go guys!!! To the moon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380649100","isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}